EMA Guidelines on Synthetic Peptide Drug Substance Characterisation: 2025 Update
A comprehensive review of EMA reflection papers and guideline updates affecting identity, purity, and impurity control for synthetic peptide APIs in EU regulatory submissions.
Background: EMA's Evolving Approach to Peptide APIs
The European Medicines Agency has progressively refined its expectations for synthetic peptide drug substance characterisation over the past decade. The 2025 update to the CHMP reflection paper on peptides introduces important clarifications on impurity thresholds, structural characterisation depth, and process validation expectations that affect CTD Module 3.2.S submissions for EU marketing authorisation applications (MAAs).
Key 2025 Guideline Changes
The updated reflection paper introduces tiered impurity control strategies calibrated to clinical development stage. For Phase I/II IND packages, a risk-based, justification-supported approach is acceptable. From Phase III and for MAA submissions, full ICH Q3A-aligned thresholds apply: identification threshold 0.10% (or 1.0 mg TDI, whichever is lower); qualification threshold 0.15% (or 1.0 mg TDI).
Structural Characterisation by HR-MS/MS
High-resolution tandem mass spectrometry (HR-MS/MS) data for all process-related impurities above the 0.10% identification threshold is now expected in CTD 3.2.S.3.2. For peptides above 20 amino acids, circular dichroism (CD) spectroscopy for secondary structure confirmation is recommended. NMR characterisation of reference standards for quantitative impurity determination is explicitly noted as best practice.
Process Validation and Control Strategy
The 2025 update aligns with ICH Q8/Q9/Q10 quality-by-design principles, expecting a documented control strategy linking critical quality attributes (CQAs) to critical process parameters (CPPs) for SPPS synthesis, cleavage, and purification steps. Continued process verification (CPV) data requirements for commercial-scale manufacture are clarified.
Practical Implications for EU CTD Submissions
Sponsors preparing EU MAAs for peptide-based therapeutics should engage their peptide CDMO early to confirm analytical capability for HR-MS/MS impurity profiling and CD spectroscopy. The ViraChem platform at virachemical.com provides access to EU CDMOs with these capabilities pre-verified.